Olivia van Gerwen, MD
Infectious Disease · Birmingham, ALNPI 1487072393
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,853 of the $9,890 with a category attached, or 79.4%. Biomerieux Inc accounts for 84.7% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $8,732, 7.7 times the $1,138 reported in 2022.
Across 9 payments — averaging $1098.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomerieux Inc$8K
- Scynexis, Inc.$1K
- Abbott$350
- Lupin Inc.$88
- Hologic Sales And Service, LLC$21
Across 44 payments — averaging $11,234 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$494K
What the payments were for
- Consulting fees$7,85379%
- Travel & lodging$1,66917%
- Food & beverage$3694%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomerieux Inc | 5 | $8,382 |
| Scynexis, Inc. | 1 | $1,050 |
| Abbott | 1 | $350 |
| Lupin Inc. | 1 | $88 |
| Hologic Sales And Service, LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Alinity m$350
How this compares
$9,890 in reported general payments places this provider in the 75th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 48 | $213,212 |
| PrezcobixDarunavir/Cobicistat | 30 | $71,156 |
| TivicayDolutegravir Sodium | 31 | $66,998 |
| JulucaDolutegravir/Rilpivirine | 13 | $41,080 |
| Ceftazidime | 15 | $3,010 |
| Estradiol Valerate | 12 | $1,873 |
| Flunisolide | 12 | $536 |
| Spironolactone | 18 | $455 |
| Omega-3 Acid Ethyl Esters | 13 | $285 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $278 |
| Gabapentin | 40 | $194 |
| Sure Comfort Pen NeedlePen Needle, Diabetic | 11 | $179 |
| Atorvastatin Calcium | 56 | $155 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $115 |
| Testosterone Cypionate | 12 | $108 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Birmingham
- John BaddleyBirmingham$113K
- Christina MuznyBirmingham$111K
- Sonya HeathBirmingham$80K
- William GeislerBirmingham$63K
- Edward HookBirmingham$61K
- Edgar OvertonBirmingham$46K
- Jane SchwebkeBirmingham$42K
- Peter PappasBirmingham$25K
- Jeanne MarrazzoBirmingham$23K
- Todd McCartyBirmingham$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.